Trials
5 active
7 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “INCB123667 will be administered at the protocol defined dose.”In the company’s words, NCT07797283 on ClinicalTrials.gov
- Tested for
- Ovarian Cancer (3 trials), Renal Impairment, Hepatic Insufficiency, Liver Diseases
- Main trialPhase 3
- “The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.”In the company’s words, NCT07214779 on ClinicalTrials.gov
Other drugs for Ovarian Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab SoravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
Coming up5
- 4 Jan 2027Phase 1 trial completes · ClinicalTrials.gov
- 13 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- 27 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- 12 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- 1 May 2032Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 17 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT07214779
- 17 NovCompletion date moved: 2028-11-15 to 2027-10-12 · ClinicalTrials.gov NCT07214779
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 12 Oct 2027 | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | |
| Phase 3Not yet recruiting | 1 May 2032 | Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 | |
| Phase 2Recruiting | 27 Apr 2027 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | |
| Phase 1Recruiting | 4 Jan 2027 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease | |
| Phase 1Recruiting | 13 Apr 2027 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment | |
| Phase 1Completed | 10 Dec 2025 | Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants | |
| Phase 1Completed | 17 May 2026 | A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026